Gufic Biosciences Limited
GUFICBIO · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹226.34.
Piotroski F-score 6/9 — quality of earnings & balance sheet.
Investability checklist
- ✕ROE above 15%10.1%
- ✕Low debt (D/E < 0.5)0.61x
- ✕Positive free cash flow
- ✓Revenue growth > 10%23%
- ✓Earnings growing183%
- ✕Net margin ≥ 10%6.8%
- ✓Current ratio > 1.51.55
- ✕Below our fair value
- ✕Margin of safety ≥ 20%
- ✓Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 4.21
- ✕Piotroski ≥ 76/9
1-year price
EOD · 2026-06-16Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Quarterly results
Annual financials
Shareholding
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
SWOT snapshot
Strengths
- •Financially solid — Altman Z 4.21.
Opportunities
- •Earnings growing (183% YoY).
- •Revenue growing (23% YoY).
Threats
- •Trades ~24% above our estimated fair value.
About Gufic Biosciences Limited
Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, and South America. The company manufactures APIs and bulk drugs, such as antifungals, anaethetics, immuno suppressants, anginotensin receptor blocker, and intermediates for antifungals. It also manufactures lyophilized injections for antibiotic, antifungal, cardiac medications, infe
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.